NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

In your fantasy model please include what the government is willing to pay for L then subtract 15% that goes to Advent because LP chose to externalize the CDMO.

>>But the U.K. government likely won’t be paying for it after an independent agency separately issued draft guidance concluding that the benefits of Leqembi “cannot be considered good value for the taxpayer.”

>>The reality is that the benefits this first treatment provides are just too small to justify the significant cost,” said Dr. Samantha Robers, chief executive of the National Institute for Health and Care Excellence, or NICE.

>>The agency estimated about 70,000 people in Briton might benefit from Leqembi. The drug is still available to be prescribed if patients pay for it privately. In the U.S., it costs about $26,000 per patient per year.

https://abcnews.go.com/amp/Health/wireStory/uk-drug-regulator-approves-alzheimers-drug-government-pay-113052788